Monthly Archives: February 2010
Merck, Lilly, Pfizer: One for All and All for One
Just a month after Andrew Witty’s announcement that GSK will make more than 13,500 of its malaria compounds available to all, Pfizer, Merck, and Eli Lilly have thrown their do-gooder hats into the ring as well.
Together, the three drug giants will pull together an undisclosed dollar amount in seed funding and create the independent, non-profit [...]
Posted in Strategy Tagged ACRG, Andrew Witty, Cancer, Diseases & Conditions, Eli Lilly, Health, Lung cancer, Pfizer 1 Comment
FDA and GSK on the Hunt for Stolen Drugs
Image by Johnny Grim via Flickr
We typically don’t get emails from FDA asking for information about stolen goods with massive bold letters, but that’s what just came into our inbox. Looks like a transport truck containing a mix of GlaxoSmithKline’s pharmaceutical and over-the-counter medications was jacked in Puerto Rico on January 29, and the feds [...]
Posted in FDA, News Tagged Food and Drug Administration, GSK, Medicine, Pharmaceutical drug, Puerto Rico, Security, Theft 1 Comment
Europe: Of Apes and Ombudsmen
Guest blog by Reflector, Pharm Exec Europe’s Brussels correspondent.
This column has frequently drawn attention to the complexities of getting anything done in Europe. A brilliant researcher can explore visionary horizons, an ambitious entrepreneur can offer a package of goods or services of inestimable value, but the degree of control and regulation becomes more intense [...]
Posted in Europe, Global, Regulatory Tagged animal research, animal rights activism, European Commission, European Ombudsman, European Union, Pharma Leave a comment

US and Europe At Risk from Substandard Medicines